Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Proof of Concept Study Evaluating Intravitreal AAVCAGsCD59 for the Treatment of Wet Age-Related Macular Degeneration (AMD)

Trial Profile

A Phase 1 Proof of Concept Study Evaluating Intravitreal AAVCAGsCD59 for the Treatment of Wet Age-Related Macular Degeneration (AMD)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2019

At a glance

  • Drugs HMR-59 (Primary) ; Aflibercept; Bevacizumab; Prednisolone; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Hemera Biosciences
  • Most Recent Events

    • 06 Jan 2019 Planned number of patients changed from 10 to 25.
    • 13 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 01 Sep 2018 Planned initiation date changed from 6 Aug 2018 to 14 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top